Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinostamustine in Relapsed/Refractory Hematologic Malignancies
NCT02576496Phase 1Completed
- Sponsor
- Mundipharma
- Start
- Apr 2016
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of tinostamustine in multiple myeloma (MM), Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL) and 2 more (7 arms), sponsored by Mundipharma. Primary endpoints: Overall Response Rate, Clinical Benefit Rate and 2 more. Started Apr 2016; status: completed.
02
Drugs
tinostamustine
03
Conditions
multiple myeloma (MM)Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT02576496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576496.